IVIG in Autoimmune Autonomic Ganglionopathy

Status: Recruiting

Treatment for Auto-Immune Autonomic Ganglionopathy with IVIG: The purpose of the study is to determine whether administering intravenous immune globulin (IVIG) (administering immune globulin directly into the bloodstream) helps to improve the symptoms of orthostatic hypotension (a sudden fall in blood pressure when standing up) and quality of life in men and women who have autoimmune autonomic ganglionopathy (AAG). http://clinicaltrials.gov/ct2/show/NCT01522235

Eligibility: The study is open to people with autoimmune autonomic ganglionopathy between the ages of 18 – 85 years. 

IRB#: S12-00561

Sponsor: National Institutes for Health